X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The Company intends to use the net proceeds from the offering for to fund research and development activities, such as THIO-101 (6-Thio-2-Deoxyguanosine) for the treatment of patients with non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 23, 2024
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent. It is being evaluated in combination with Libtayo (cemiplimab) for the treatment of advanced non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in phase 2 clinical trials in combination with Libtayo for the treatment of non-small cell lung cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
THIO (6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development in combination with Libtayo (cemiplimab) to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Details:
MAIA currently intends to use the net proceeds to fund research and development activities, including for the development of THIO-101 (6-Thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 15, 2023
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in glioblastoma.
Lead Product(s): 6-Thio-2-Deoxyguanosine
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with an immune checkpoint inhibitor (CPI) in patients with advanced Non-Small Cell Lung Cancer.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
The Company intends to use the proceeds from the offering to fund the ongoing clinical trials of THIO including THIO-101 (6-Thio-2'-deoxyguanosine), pre-clinical development of second-generation of telomere targeting compounds, and other research and development activities.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 27, 2023
Details:
The Company intends to use the net proceeds to fund the ongoing clinical trials of THIO, including THIO-101 (6-thio-2'-deoxyguanosine) and pre-clinical development of second-generation of telomere targeting compounds.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 24, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development for hepatocellular carcinoma. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Undisclosed
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
THIO (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer (NSCLC). Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with Regeneron’s anti-PD1 therapy, Libtayo® (cemiplimab).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
THIO-101 is designed to evaluate THIO’s potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of Regeneron’s anti-PD1 therapy, Libtayo® (cemiplimab).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC, in sequential administration with cemiplimab (Libtayo®), a PD-1 inhibitor.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
The scientific exchange presentation will summarize an unexpected, yet promising, property of MAIA’s THIO platform, a modified nucleoside - 6-thio-2’-deoxyguanosine (6-thio-dG;), as a potential anticancer agent.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
The Company intends to use the net proceeds to fund the first part of the Phase 2 trials of the Company’s product candidate THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 01, 2022
Details:
The Company intends to use the net proceeds from the initial public offering to fund the first part of the Phase 2 trials of the Company’s product candidate THIO (6-thio-2-deoxyguanosine), pre-clinical development of second-generation of telomere targeting compounds.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2022
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is an investigational telomere-targeting agent in development for the treatment of patients with telomerase-positive cancers.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
The proceeds of the financing will advance MAIA’s programs and will support the initiation of a Phase 2 clinical trial (THIO-101) evaluating the administration of THIO followed by cemiplimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC).
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.4 million Upfront Cash: Undisclosed
Deal Type: Financing March 16, 2022
Details:
Under the terms of the collaboration, MAIA will sponsor and fund the planned clinical trial and Regeneron will provide Libtayo. The clinical trial will evaluate the safety and efficacy of four dose levels of THIO, for the treatment of cancer, followed by Libtayo.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Cemiplimab
Therapeutic Area: Oncology Product Name: THIO
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: MAIA Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2021
Details:
In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses.
Lead Product(s): 6-Thio-2-Deoxyguanosine,Anti-PD-L1 therapy
Therapeutic Area: Oncology Product Name: Thio
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
